The hematopoietic system continuously renews itself; billions of blood cells are produced each day in the bone marrow by the regulated proliferation and differentiation of hematopoietic stem cells (HSCs). In patients with cancer, chemotherapy frequently causes acute bone marrow injury that leads to aplasia followed by extensive remodeling of the stromal compartment [1] [2] [3] [4] . In addition to acute cytotoxicity, patients that have received previous chemotherapy often show irreversible chronic bone marrow damage, leading to impaired hematopoietic reserve and function, reduced granulocyte colony-stimulating factor (G-CSF)-induced mobilization of HSCs and delayed engraftment after transplantation [4] [5] [6] [7] [8] . Functional defects in HSCs, stromal cell activities or both have been reported after conventional chemotherapy [3] [4] [5] 7, [9] [10] [11] , but the underlying mechanisms remain unresolved.
a r t i c l e s
The hematopoietic system continuously renews itself; billions of blood cells are produced each day in the bone marrow by the regulated proliferation and differentiation of hematopoietic stem cells (HSCs). In patients with cancer, chemotherapy frequently causes acute bone marrow injury that leads to aplasia followed by extensive remodeling of the stromal compartment [1] [2] [3] [4] . In addition to acute cytotoxicity, patients that have received previous chemotherapy often show irreversible chronic bone marrow damage, leading to impaired hematopoietic reserve and function, reduced granulocyte colony-stimulating factor (G-CSF)-induced mobilization of HSCs and delayed engraftment after transplantation [4] [5] [6] [7] [8] . Functional defects in HSCs, stromal cell activities or both have been reported after conventional chemotherapy [3] [4] [5] 7, [9] [10] [11] , but the underlying mechanisms remain unresolved.
We have previously shown that the sympathetic nervous system (SNS) directs HSC trafficking by acting on nestin-positive niche cells 12, 13 . As several chemotherapeutic drugs commonly induce severe peripheral neuropathies (for example, vinca alkaloids, taxanes and platinum-based drugs) 14 , we hypothesized that chemotherapyinduced neuropathy in the bone marrow is a crucial lesion preventing hematopoietic regeneration.
RESULTS

Neurotoxic chemotherapy impairs bone marrow regeneration
We treated mice with seven cycles of cisplatin (Fig. 1a) to induce a sensory neuropathy similar to that observed clinically 15 . Four or eight weeks after the last injection, bone marrow nucleated cells (BMNCs), hematopoietic progenitors (CFU-C) and Lin − Sca1 + c-Kit + cell counts in these mice had completely recovered ( Supplementary  Fig. 1a-f ). Cisplatin-induced neuropathy has been reported to largely affect sensory nerves 15 . In agreement, cisplatin-treated mice showed sensory neuropathy 4 weeks after the last injection of cisplatin (Fig. 1b) . At that time, transplantation of fresh healthy BMNCs in cisplatin-or saline-treated mice significantly reduced survival in the cisplatin-treated group (by 33%, P < 0.05; Fig. 1c ) due to reduced hematopoietic activity, as shown by bone marrow aplasia ( Fig. 1d) and severe pancytopenia in killed moribund mice (Supplementary Table 1 ). Four weeks after transplantation, the bone marrow of surviving cisplatin-treated mice was still severely aplastic and showed marked reductions in the numbers of progenitors and HSC-enriched Lin − Sca1 + c-Kit + Flt3 − (LSKF) cells (Supplementary Fig. 2a-c) . These results suggest that previous cisplatin treatment alters the host bone marrow microenvironment, impairing hematopoietic recovery.
To further investigate the specificity of neurotoxic chemotherapy drugs, we compared treatment with cisplatin to treatment with carboplatin, a non-neurotoxic drug of the same chemical family, and to treatment with vincristine, another classical neurotoxic chemotherapeutic agent. We assessed whether cisplatin and vincristine caused sympathetic neuropathy in the bone marrow by staining for bone marrow SNS fibers with an antibody to the catecholaminergic enzyme tyrosine hydroxylase (Th). Both drugs reduced the density of Th + fibers by 80% compared with vehicle control or carboplatin treatment (Fig. 1e,f) . Furthermore, whereas the recovery of LSKF cells (Fig. 1g) and competitive HSC reconstitution capacity (Supplementary  Table 2 ) were compromised after transplantation in cisplatin-or vincristine-treated mice, carboplatin-treated mice showed recovery similar to that of vehicle-treated controls (Fig. 1g) , suggesting that sympathetic neurotoxicity is associated with poor hematopoietic recovery after genotoxic insult.
Sympathetic nerves are required for bone marrow recovery
To evaluate more specifically whether sympathetic innervation is required for hematopoietic regeneration, we denervated the SNS of mice by treatment with 6-hydroxydopamine (6OHDA). Consistent with previous studies 12, 16 and in contrast to a recent report 17 , sympathectomy by itself did not alter BMNC, CFU-C or hematopoietic stem cell or progenitor content or cell cycle ( Supplementary  Fig. 3a-e) . However, transplantation of wild-type (WT) BMNCs into lethally irradiated 6OHDA-or saline-treated mice (Fig. 2a) led to a significant increase in mortality in the 6OHDA-treated group (Fig. 2b) and delayed hematopoietic recovery as assessed at 4 weeks after transplantation ( Fig. 2b and Supplementary Fig. 4a,b) .
Engraftment of transplanted HSCs is a complex process that requires homing to the bone marrow and migration to the appropriate niche for survival and proliferation 18 . Neither 6OHDA nor cisplatin therapy affected progenitor homing to the bone marrow ( Supplementary Fig. 5a-e) . In addition, we observed reduced bone marrow recovery after challenging sympathectomized mice with sublethal irradiation (Supplementary Fig. 5f-i) , further suggesting that reduced bone marrow recovery is independent of homing. To confirm this, we also tested the response of the mice to 5-fluorouracil (5FU), which ablates proliferating cells while inducing quiescent HSC to repopulate the bone marrow in situ. 6OHDA-treated sympathectomized mice showed marked reductions in survival after 5FU challenge (Fig. 2c) due to hematopoietic failure (Fig. 2d, Supplementary  Fig. 6a-f and Supplementary Table 3) . Notably, neither this dose of irradiation nor 5FU treatment caused any detectable loss of Th + nerve fibers (Supplementary Fig. 7a-d) . These results suggest that SNS signals are required for HSC expansion and survival during bone marrow recovery.
To confirm the role of the SNS in regeneration, we crossed Th-cre mice 19 (which express the Cre recombinase in catecholaminergic neurons) with iDTR mice 20 (in which Cre-mediated recombination induces expression of the diphtheria toxin receptor) to produce Th-cre; iDTR mice. Diphtheria toxin injection into Th-cre; iDTR mice triggered apoptosis of peripheral sympathetic neurons (Fig. 2e) . SNS injury was still evident in the bone marrow of diphtheria toxin-injected Th-cre; iDTR mice 12 d after 5FU administration (Fig. 2f) , and these mice had reduced hematopoietic regeneration as compared to 5FU-treated control mice ( Fig. 2g and  Supplementary Fig. 6g ). These results further suggest that an intact SNS is required for bone marrow recovery.
We next assessed which adrenergic receptors mediated bone marrow regeneration. Circadian physiological HSC release is controlled largely by the β3 adrenergic receptor (β3-AR), which is expressed by niche cells 12 , whereas the β2 adrenergic receptor (β2-AR) is broadly expressed in nonhematopoietic and hematopoietic fractions, including human CD34 + cells, where it regulates progenitor migration 21 . We found overlapping functions for β2-AR and β3-AR in bone marrow recovery after treatment with 5FU, as we observed a deficit similar to that in 6OHDA-treated sympathectomized mice only when the functions of both β-ARs were inactivated ( Fig. 2h and  Supplementary Fig. 8 ). Reduced recovery after cisplatin is due to SNS injury Because deletion of the tumor suppressor gene Trp53 (encoding p53) in sympathetic neurons has been reported to promote neuronal survival after genotoxic insult 22 , we hypothesized that p53-deficient SNS nerves would be protected from chemotherapy-induced injury and that this protection would be associated with improved hematopoietic recovery. To investigate this, we crossed Th-cre mice with Trp53 flox/flox mice 23 to produce Th-cre; Trp53 ∆/∆ mice. Peripheral sympathetic neurons from cisplatin-treated Th-cre; Trp53 ∆/∆ mice did not express Trp53 after cisplatin treatment (Supplementary Fig. 9 ). Compared to control mice treated with cisplatin, similarly treated Th-cre; Trp53 ∆/∆ mice had reduced apoptosis of sympathetic neurons ( Fig. 3a) and increased numbers of bone marrow SNS fibers (Fig. 3b,c) .
We then subjected the Th-cre; Trp53 ∆/∆ mice and WT control (Trp53 flox/flox , Trp53 +/+ , Trp53 +/flox or Th-cre; Trp53 +/+ ) littermates to cisplatin treatment followed by bone marrow transplantation (as described above and shown in Fig. 1a) . Notably, we found improved survival and hematopoietic recovery (Fig. 3d,e) in cisplatintreated Th-cre; Trp53 ∆/∆ mice compared to cisplatin-treated control littermates. These results strongly support the notion that chemotherapy-induced SNS injury impairs hematopoietic regeneration after transplantation. 1g and 2c,g,h) and the SNS targets nestinexpressing niche cells to regulate HSC trafficking 13 , we hypothesized that the SNS is required for niche recovery after genotoxic insult. We treated Nes-GFP mice with saline (control) or 6OHDA and assessed regeneration after 5FU challenge. Twelve days after 5FU challenge, the bone marrow of 6OHDA-treated mice contained fewer nestin-GFP + cells and CD31 + endothelial cells, which contribute to the HSC niche 13, 24, 25 , compared to 5FU-treated controls (treated with saline rather than 6OHDA) (Fig. 4a,b) . We found no statistically significant differences in the numbers of bone osteoblasts or bone marrow macrophages ( Supplementary Fig. 10a-g ). We next imposed pharmacological β-blockade in Nes-GFP mice by treating them with SR59230A (a β3-AR antagonist) and ICI118,551 (a β2-AR antagonist) for 3 consecutive days, followed by treatment with 5FU. Twelve days later, we found reduced numbers of nestin-GFP + cells and CD31 + endothelial cells compared to control mice treated with 5-FU only (Fig. 4c,d) .
We obtained similar results in cisplatin-treated Nes-GFP mice that received a bone marrow transplant as assessed 4 weeks after transplantation (Fig. 4e,f) . As the β-adrenergic antagonists were administered before 5FU injection, our results suggest that the SNS acts acutely to protect niche constituents from genotoxic insult. Indeed, the number of nestin-GFP + cells and CD31 + endothelial cells in 6OHDA-treated or β2-and β3-antagonist-treated mice was reduced as early as 24 h after 5FU injection (Fig. 4g,h ). Taken together these data indicate that the SNS promotes hematopoietic function by protecting nestin-GFP + cells and endothelial cells from genotoxic insult. SNS injury by itself (using 6OHDA) did not alter BMNC, CFU-C or LSKF content but did increase the number of nestin-GFP + cells (Supplementary Fig. 10h,j,k) . Further, 3-d treatment with the β2 and β3 antagonists increased the percentage of proliferating (Ki67 + ) nestin-GFP + and endothelial cells (Supplementary Fig. 10i ). These results suggest that the SNS negatively regulates the size of the HSC niche. To confirm that SNS injury does not impair steady-state niche function, we transplanted nonirradiated 6OHDA-or cisplatintreated CD45.2 + mice with 1 × 10 7 BMNCs from CD45.1 + mice. In this setting, we observed an enhanced multilineage engraftment in 6OHDA-or cisplatin-treated mice compared to saline-treated control mice (Supplementary Fig. 11a,b) . Engraftment was sustained for 16 weeks in the cisplatin-treated but not the 6OHDA-treated group, probably because 6OHDA injury is rapidly reversible (~2 weeks) (data not shown). The enhanced engraftment in SNS-injured mice correlated with an increase in nestin-GFP + cell numbers ( Supplementary  Fig. 10h,k) , suggesting that the expanded niche cells were functional and capable of supporting transplanted HSC.
Chemotherapy-induced SNS injury impairs HSC mobilization
After acute administration of chemotherapy, hematopoietic recovery can be accompanied by a marked mobilization of HSCs and progenitors in the bloodstream, suggesting that marrow regeneration is associated with mobilization 26 . As the SNS regulates HSC egress 12, 16 , we tested the possibility that poor mobilization due to previous chemotherapy treatment in patients with cancer 5 could be caused by bone marrow neuropathy. We treated mice weekly with saline or cisplatin for 7 weeks; after a 4-week recovery period, we induced HSC and progenitor mobilization with G-CSF (Fig. 5a) . Cisplatin-treated mice showed a ~50% reduction in the number of mobilized CFU-C, LSKF and long-term culture-initiating cells (LTC-IC) in the blood (Fig. 5b  and Supplementary Table 4) . Furthermore, competitive repopulation experiments revealed reduced HSC content in the G-CSF-mobilized blood of cisplatin-treated mice (Fig. 5c) . We detected no statistically significant change in the numbers of progenitors or LSKF cells (Fig. 5d) in the bone marrow of these mice, indicating that the reduced mobilization after chemotherapy treatment was not due to lower numbers of HSCs and progenitors. To exclude the possibility of an HSC-autonomous defect, we lethally irradiated cisplatin-or saline-treated mice, transplanted them with fresh WT BMNCs and allowed them to recover for 16 weeks (Fig. 5e) . At this time point, bone marrow recovery was complete, and HSC content (as determined by competitive reconstitution with limiting dilution) was similar in cisplatin-and saline-treated mice ( Supplementary  Fig. 12a,b and Supplementary Table 5) . However, there was still an ~50% reduction in mobilization efficiency after G-CSF administration in cisplatin-compared to saline-treated mice (Fig. 5f,g ), indicating that cisplatin treatment produces bone marrow neuropathy, which markedly compromises G-CSF-induced mobilization.
Neuroprotection rescues marrow function after chemotherapy
On the basis of these results, we predicted that interventions that protect neural function might also restore hematopoietic regeneration. To test this hypothesis, we engineered a chimeric GDNF-Fc protein by fusing the C-terminal end of mouse GDNF, which has been reported to rescue preganglionic sympathetic neurons after adrenomedullectomy 27 , with the Fc region of human IgG1. Purified (Supplementary Fig. 13a) . GDNF-Fc administration to cisplatin-treated mice reduced sensory neuropathy (Supplementary Fig. 13b,c) and after bone marrow transplantation led to increased survival, accelerated bone marrow recovery and increased density of bone marrow Th + fibers compared to mice treated with cisplatin alone (Supplementary Fig. 13b-h) . We obtained similar results in the 5FU model in which GDNF-Fc administration promoted survival and accelerated bone marrow recovery in 6OHDA-treated mice (Supplementary Fig. 14a-c) .
GDNF-Fc was able to induce neural differentiation of PC12ES cells, demonstrating its activity in vitro
We next administered 4-methylcatechol (4-MC), a drug that has been reported to induce endogenous nerve growth factor (NGF) production and protect SNS fibers 28, 29 , during the seven cycles of cisplatin chemotherapy. This treatment reduced sensory neuropathy (Supplementary Fig. 15a ) and restored the normal fiber density of bone marrow Th + nerves in the cisplatin-treated and 4-MC-treated group compared to the cisplatin-and saline-treated control group (Fig. 6a) . Moreover, 4-MC treatment enhanced survival ( Fig. 6b ; P < 0.05, log-rank test), accelerated bone marrow regeneration after transplantation (Fig. 6c and Supplementary Fig. 15b,c) and Table 6 ). 4-MC treatment also restored normal numbers of nestin-GFP + and endothelial cells in cisplatin-treated mice (Fig. 6c) . These results indicate that neuroprotection by 4-MC from cisplatin-induced SNS injury accelerates bone marrow regeneration. To evaluate further whether the effect of 4-MC was specifically due to the recovery of SNS fibers, we administered 4-MC (daily, days −5 to 0) during the 6OHDA treatment (single injection on day −5 and day −3), and on day 0, we injected 5FU to enforce bone marrow regeneration. 4-MC administration protected Th + fibers (Supplementary Fig. 16a ), promoted hematopoietic recovery (Fig. 6d,e and Supplementary  Fig. 16b,c) and completely protected mice from death due to bone marrow aplasia (Fig. 6e) . 4-MC also increased HSC recovery, as measured by LTC-IC assay (Supplementary Table 7) , and restored the numbers of nestin-GFP + cells and CD31 + endothelial cells 12 d after 5FU treatment (Fig. 6f) without affecting bone marrow macrophage or bone osteoblast numbers (Supplementary Fig. 17a-e) . Taken together these results show that neuroprotection can enhance bone marrow recovery after SNS injury, probably by maintaining the ability of the SNS to promote survival of niche cells after genotoxic insult. NGF signals through two receptors, the p75 low-affinity receptor and TrkA (encoded by Ntrk1). TrkA seems to be the dominant receptor for NGF because the phenotype of Ntrk1 −/− mice resembles that of Ngf −/− mice 30, 31 . However, TrkA is not expressed exclusively in neurons but is also expressed in non-neural stromal cells 32 . To investigate whether the effect of 4-MC on bone marrow recovery was specifically due to protection of neurons, we analyzed Ta1-cre:Ntrk1 neo/neo mice, in which TrkA is expressed exclusively in neurons but not other cell types 33 . Sympathectomized Ta1-cre:Ntrk1 neo/neo mice treated with 4-MC showed recovery comparable to that of sympathectomized WT control mice treated with 4-MC ( Fig. 6g and Supplementary Fig. 18) , suggesting that the action of 4-MC is mediated by TrkA signaling in neurons. To evaluate further the effect of neuroprotection, we analyzed whether 4-MC or GDNF-Fc treatment could restore G-CSFinduced mobilization in cisplatin-treated mice. As described above (Fig. 5b) , the numbers of G-CSF-mobilized progenitors and LSKF cells in blood were markedly reduced in cisplatin-treated mice (Fig. 6h) . Treatment with 4-MC (daily injection through the 6 weeks of cisplatin treatment; Fig. 6h ) or GDNF-Fc (daily injection for 2 weeks starting the day after the last dose of cisplatin; Supplementary Fig. 19 ) restored G-CSF-induced mobilization. Thus, 4-MC maintains hematopoietic function by specifically protecting SNS fibers in the bone marrow, offering a new avenue for clinical intervention.
DISCUSSION
Here we show that neurotoxicity from anticancer chemotherapy impairs bone marrow regeneration after transplantation. Our results suggest that SNS signaling exerts crucial functions immediately after genotoxic insult (for example, irradiation or 5FU treatment) to promote the survival of niche constituents, thereby promoting efficient hematopoietic recovery. Our data support the notion that neurotoxic chemotherapy agents can damage autonomic nerves in the bone marrow and compromise HSC mobilization and hematopoietic regeneration. These studies provide proof of principle that neuroprotection may preserve hematopoietic and mobilization reserves after neurotoxic chemotherapy. Recent studies have identified the vasculature (including endothelial cells 34 ), Cxcl12-abundant reticular (CAR) cells 35 , nestin-positive mesenchymal stem cells 13 and leptin receptor-expressing cells 25 as constituents of a potential HSC niche in the bone marrow 36 . Notably, our results indicate that nestin-positive and endothelial cells follow similar recovery kinetics after bone marrow injury, suggesting a functional dependence. Gap junctions linking autonomic nerves and perivascular stromal cells 37 might contribute to the synchronized response of the vascular niche. Indeed, the gap junction protein Gja1 (also called connexin43) is required for efficient bone marrow regeneration 38 . Furthermore, endothelial cells and pericytes are known to have intricate interactions involving paracrine and/or juxtacrine signaling 39 . For example, pericytes promote endothelial cell survival by inducing an autocrine vascular endothelial growth factor (VEGF) signaling loop in endothelial cells 40 , and VEGF signaling is crucial for bone marrow regeneration 1 . Similarly, endothelial cell-derived platelet-derived growth factor B (PDGF-B) is required for pericyte recruitment to blood vessels during angiogenesis 39 . Further studies are needed to evaluate in greater detail the exact type(s) of stromal cells targeted by the SNS.
Although our results indicate that neural signals are crucial for HSC niche recovery, they also suggest that chemotherapy (in the case of cisplatin) injures stromal cells outside of the HSC niche. This conclusion is based on our findings that in cisplatin-treated mice, neuroprotection with 4-MC allowed full HSC recovery but incomplete recovery of clonogenic progenitors and total bone marrow cellularity. In contrast, 4-MC neuroprotection in 6OHDA-treated mice (in which only SNS fibers are injured) allowed complete HSC, CFU-C and bone marrow cellularity recovery. This suggests that cisplatin damages stromal cells that facilitate the recovery of clonogenic progenitors and their differentiated progeny. This possibility is also suggested by differences in the recovery of HSC and total bone marrow cells after treatment with vincristine as compared to cisplatin. Taken together, our results support the notion that cisplatin-induced neuropathy alters niche function after stress and that, in the steady state, the SNS negatively regulates niche size.
Although much attention in studies of chemotherapy-induced neuropathy has been devoted to the most clinically visible sensory neural dysfunctions 41 , our results highlight an insidious form of autonomic neuropathy of the bone marrow that may present a risk for patients requiring further intensive therapy (for example, bone marrow transplantation). Thus, neuroprotective agents during conventional chemotherapy may prevent long-term bone marrow injury. Additionally, neuroprotective agents may provide a therapeutic option to increase bone marrow function in patients previously treated with chemotherapy.
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